Methods and compositions for the sustained release of chromium

• US 10,245,325 B2
• Filed: 06/12/2017
• Issued: 04/02/2019
• Est. Priority Date: 03/13/2007
• Status: Expired due to Fees

• Current Assignee: Nutrition21 LLC
• Original Assignee: JDS Therapeutics LLC
• Inventors: Komorowski, James R.
• Primary Examiner(s): Pagonakis, Anna
• Application Number:
  US15/620,542
• Publication Number:
  US 20170304360A1
• Time in Patent Office: 659 Days
• CPC Class Codes: A23L 33/165 Complexes or chelates
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2250/1586 Chromium
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/4172 Imidazole-alkanecarboxylic acids, e.g. histidine
• CPC Class Codes: A61K 31/4402 only substituted in position 2, e.g. pheniramine, bisacodyl
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 47/545 Heterocyclic compounds A61K47/558 takes precedence
• CPC Class Codes: A61K 47/547 Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.

Claims

1. A composition comprising:

a chromium complex comprising;

an amount of a fast-acting chromium complex; and

an amount of a slow-acting chromium complex;

wherein the fast-acting chromium complex is absorbed more quickly by an individual to whom it is administered than the slow-acting chromium complex;

wherein the amount of a fast acting chromium complex and the amount of the slow-reacting chromium complex are formulated to have a molar ratio of chromium between 1;

10 and 10;

1.

2. The composition of claim 1, wherein the chromium complex is a hydrophobic chromium complex.

3. The composition of claim 1, wherein the fast-acting chromium complex is hydrophilic and the slow-acting chromium complex is lipophilic.

4. The composition of claim 1, wherein the slow-acting chromium complex is lipophilic.

5. The composition of claim 1, wherein the fast-acting chromium complex is hydrophilic.

6. The composition of claim 1, wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:

8 and 8;

1.

7. The composition of claim 1, wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:

4 and 4;

1.

8. The composition of claim 1, wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:

2 and 2;

1.

9. The composition of claim 1, wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium of about 1:

1.

10. The composition of claim 1, wherein the fast-acting chromium complex is a chromium histidinate complex.

11. The composition of claim 1, wherein the fast-acting chromium complex is a chromium nicotinate complex.

12. The composition of claim 1, wherein the fast-acting chromium complex is selected from the group consisting of chromium acetate, chromium chloride, chromium histidinate, and chromium nicotinate, or any combination thereof.

13. The composition of claim 1, wherein the fast-acting chromium complex is selected from the group consisting of chromium histidinate, chromium trihistidinate, chromium polyhistidinate, or any combination thereof.

14. The composition of claim 1, further comprising metformin.

15. The composition of claim 1, further comprising a pharmaceutically acceptable vehicle.

16. The composition of claim 1, wherein the slow-acting chromium complex is selected from the group consisting of chromium picolinate, chromium tripicolinate, or a combination thereof.

17. The composition of claim 1, wherein the slow-acting chromium complex is chromium picolinate.

18. The composition of claim 1, wherein the slow-acting chromium complex is chromium tripicolinate.

19. The composition of claim 1, wherein the slow-acting chromium complex provides a glucose lowering effect.

20. The composition of claim 1, wherein the slow-acting chromium complex provides a glucose stabilization effect for at least 10 hours.